New research from Stanford recasts the brain vasculature, commonly known as the “blood-brain barrier,” as an active interface that, contrary to other theories, allows many proteins from the blood into brain cells.
To get up to speed on the revolutionary pace of coronavirus vaccine development, Paul Costello spoke to Stanford Medicine's Bali Pulendran, PhD, a professor of pathology and of microbiology and immunology for a 1:2:1 podcast.
Chemical engineering Professor Gerald Fuller has received the Tau Beta Pi Teaching Award for the 2019–2020 academic year, and 12 other faculty members and instructors have been added to the Teaching Honor Roll by the Stanford chapter of this nationwide honors society for the engineering profession.
Stanford Vice Provost and Dean of Research Kathryn Moler wants all research resources to be as readily available as books in a library. This model would enable faculty and students to pursue the most innovative research in flexible, collaborative teams.
At the Academic Council meeting, President Marc Tessier-Lavigne discussed how Stanford is pivoting its Long-Range Vision in light of COVID-19. ChEM-H Baker Family Co-Director, Professor Chaitan Khosla, described the new Innovative Medicines Accelerator.
Plans for Stanford’s new Innovative Medicines Accelerator arose before the COVID-19 pandemic struck, but now its programs are focused entirely on helping faculty generate and test new medicines to slow the spread of the disease.
Scientists at Stanford Medicine are investigating whether a molecule called interferon-lambda can help people with mild cases of COVID-19 feel better and reduce their transmission of the disease-causing virus.
Researchers have developed a way to combine insulin with a second hormone known as amylin, to create a two-in-one injection that could, if proven safe and effective in human trials, make it easier for diabetics to more effectively control their blood sugar levels.